Interaction With HIV Antiretroviral Agents

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 23, 2016

Primary Completion Date

December 7, 2016

Study Completion Date

December 7, 2016

Conditions
HIV-DDI
Interventions
DRUG

Riociguat (Adempas, BAY 63-2521)

0.5 mg, Oral (fasted conditions), 1 single dose

DRUG

ATRIPLA

600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily

DRUG

COMPLERA

200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily

DRUG

STRIBILD

150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily

DRUG

TRIUMEQ

600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily

DRUG

Antiretroviral protease inhibitor

Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents

Trial Locations (2)

32803

Orlando

02118

Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY